The data on countries with a current vaccination campaign was compiled from government sources by Our World in Data. Many countries, particularly those in the developing world, where governments have struggled to procure vaccines, are not yet vaccinating residents at all.
Most countries are using vaccines from Pfizer-BioNTech or Moderna, both of which require two doses. Two of the countries with among the world’s highest vaccination rates, the United Arab Emirates and Bahrain, are also using a vaccine developed by the Chinese company Sinopharm, which has not been approved for use in the United States or the Europe Union.
The table shows which countries have vaccinated their residents at the fastest rates since the start of their immunization campaigns, and which vaccinated the most in the past seven days. It also shows, at current speeds and immunization levels, how long it will take for at least half the residents in each country to receive at least one dose of a vaccine.
Israel, for example, will reach half its population with at least one dose of the vaccine in just four weeks at its current rate, though the vaccination campaign and the vaccinated rate excludes Palestinians in the occupied West Bank and blockaded Gaza Strip, who may have to wait several months for widespread distribution. Most European countries are months away from reaching Israel’s levels of vaccination.
Part of the disparity stems from when vaccines were approved in each country. Health authorities in the European Union approved the Pfizer vaccine 10 days later than their counterparts in the United States and nearly three weeks after U.K. officials.
And distribution lagged in some countries even after the vaccine was approved. The Netherlands, one of Europe’s richest countries, was the last in the European Union to begin its vaccination campaign — on Jan. 6, a week and a half after neighboring Germany and almost a month after the United Kingdom. The Dutch health minister attributed the delay to the need for proper preparations.
Europe’s slow vaccine rollout has been hampered by supply shortages, a lack of nurses and burdensome paperwork. Criticism of the EU’s procurement strategy has grown louder as new variants of the virus threaten to take hold on the continent.
Hungarian authorities recently broke with the bloc to approve Russia’s Sputnik V vaccine and the Oxford-AstraZeneca vaccine. Hungary also agreed to purchase China’s Sinopharm vaccine.
If Europe is moving slowly, almost all nations in the developing world are further behind, and in most of them, inoculations have not even begun. Wealthy countries have preordered more than half the doses that could come to market by the end of the year, in many cases enough to vaccinate their populations several times over. Many poorer nations may be able to vaccinate 1 in 5 residents, at most, by then.